# PCVX catalysts: Vaxcyte, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/pcvx/catalysts

> Vaxcyte, Inc. (PCVX) has 6 upcoming catalysts. The next is the VAX-31 topline data readout, 1H 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA catalysts for PCVX?

Vaxcyte, Inc. (PCVX) has 6 upcoming catalysts. The next is the VAX-31 topline data readout, 1H 2027. Press release filed with the SEC (EX-99): "Enrollment in the modified study is expected to proceed by the end of the third quarter of this year with topline data from both the primary immunization series and the booster dose by the end of the first half of 2027." [Calendar and source filings](https://sec-api.dev/companies/pcvx/catalysts)

Source: Press release filed with the SEC (EX-99), accession 0001649094-25-000096, https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm (retrieved 2026-11-12). Last confirmed 2026-11-04. Cite: https://sec-api.dev/companies/pcvx/catalysts#answer

## Company

| Field | Value |
| --- | --- |
| Name | Vaxcyte, Inc. |
| Ticker | PCVX (Nasdaq) |
| SEC CIK | 1649094 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/pcvx |

## Cash runway

Cash $2.26B as of 2026-09-30; quarterly burn $224.1M; about 30.3 months of runway at that rate (XBRL company facts, accession 0001649094-26-000054).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Oct 2022 | [Vaxcyte, Inc. topline data readout](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | completed, positive | "In October 2022, we announced positive topline results from both the Phase 1 and Phase 2 portions of the study." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm)) |
| Sep 2024 | [VAX-31 topline data readout](https://sec-api.dev/pdufa/vax-31) | PCVX |  | completed, positive | "•In September 2024, prior to the initiation of our VAX-31 adult Phase 3 program, we announced positive topline results from a Phase 1/2 study of VAX-31 in adults." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000054/pcvx-20260930.htm)) |
| Dec 2024 | [VAX-31 trial start](https://sec-api.dev/pdufa/vax-31) | PCVX | IPD in Infants | completed | "•Initiated Phase 2 Study Evaluating VAX-31 for the Prevention of IPD in Infants: In December 2024, we announced the initiation of the Phase 2 study of VAX-31 in healthy infants and that the first study participants have been dosed." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm)) |
| February 25, 2025 | [Vaxcyte, Inc. earnings report](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | completed | "Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/pcvx-20250225xexx991.htm)) |
| Mar 2025 | [VAX-24 interim data readout](https://sec-api.dev/pdufa/vax-24) | PCVX |  | completed, positive | "•Announced Positive VAX-24 Infant Phase 2 Data: In March 2025, the Company announced positive interim data from the VAX-24 infant Phase 2 dose-finding study, and in November 2025 shared final safety, tolerability and immunogenicity results that were consistent with the interim findings." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/pcvx-20260224xexx991.htm)) |
| March 31, 2025 | [VAX-24 topline data readout](https://sec-api.dev/pdufa/vax-24) | PCVX |  | completed, positive | "SAN CARLOS, Calif., March 31, 2025  Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today shared positive topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, the Companys 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Prevnar 20® (PCV20) in healthy infants." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/d848914dex991.htm)) |
| mid-2025 | [VAX-31 trial start](https://sec-api.dev/pdufa/vax-31) | PCVX |  | scheduled | "-- Company Expects to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability and Immunogenicity Data in 2026 --" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000073/pcvx20250507-exx991.htm)) |
| May 7, 2025 | [Vaxcyte, Inc. earnings report](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | completed | "Vaxcyte Reports First Quarter 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000073/pcvx20250507-exx991.htm)) |
| August 6, 2025 | [VAX-31 earnings report](https://sec-api.dev/pdufa/vax-31) | PCVX |  | completed | "Vaxcyte Reports Second Quarter 2025 Financial Results and Provides Business Update, Highlighting Key Clinical and Regulatory Progress for VAX-31, a Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV)" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm)) |
| August 25, 2025 | [Vaxcyte, Inc. primary completion](https://sec-api.dev/companies/pcvx/catalysts) | PCVX | Pneumococcal Vaccines | completed | "NCT05844423 (Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-25 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05844423)) |
| late 2025 | [VAX-24 topline data readout](https://sec-api.dev/pdufa/vax-24) | PCVX |  | scheduled | "For the pediatric indication, we expect to announce the topline safety, tolerability and immunogenicity data from the VAX-24 infant Phase 2 study primary immunization series by the end of the first quarter, followed by topline data from the booster dose by the end of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/pcvx-20250225xexx991.htm)) |
| November 4, 2025 | [VAX-24 earnings report](https://sec-api.dev/pdufa/vax-24) | PCVX |  | completed | "Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/pcvx20251104-exx991.htm)) |
| November 4, 2025 | [VAX-24 interim data readout](https://sec-api.dev/pdufa/vax-24) | PCVX |  | completed, positive | "Today, the Company shared the final safety, tolerability, and immunogenicity results from this study that are consistent with the previously reported positive interim data and show that VAX-24 elicited robust, dose-dependent immune responses, with little to no evidence of carrier suppression observed." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000112/pcvx20251104-exx991.htm)) |
| Dec 2025 | [VAX-31 trial start](https://sec-api.dev/pdufa/vax-31) | PCVX | invasive pneumococcal disease | completed | "•Initiated OPUS-1, the Pivotal Phase 3 Noninferiority Trial: In December 2025, the Company dosed the first participants in the OPUS-1 trial evaluating VAX-31 for the prevention of invasive pneumococcal disease (IPD) and pneumonia in adults." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/pcvx-20260224xexx991.htm)) |
| 2026 | [VAX-31 NDA/BLA submission](https://sec-api.dev/pdufa/vax-31) | PCVX |  | scheduled | "We look forward to delivering multiple anticipated Phase 3 data readouts in 2026 and 2027 to support our potential BLA submission for the VAX-31 adult indication." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm)) |
| February 24, 2026 | [Vaxcyte, Inc. earnings report](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | completed | "Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000005/pcvx-20260224xexx991.htm)) |
| mid-2026 | [VAX-31 topline data readout](https://sec-api.dev/pdufa/vax-31) | PCVX |  | delayed | "Based on these findings, the Company has selected the VAX-24 Mid dose as the basis for advancement of an optimized dose formulation to a potential Phase 3 program and, pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026, plans to initiate an infant Phase 3 study with either VAX-24 or VAX-31." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/d848914dex991.htm)) |
| mid-2026 | [VAX-24 trial start](https://sec-api.dev/pdufa/vax-24) | PCVX |  | scheduled | "Based on these findings, the Company has selected the VAX-24 Mid dose as the basis for advancement of an optimized dose formulation to a potential Phase 3 program and, pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026, plans to initiate an infant Phase 3 study with either VAX-24 or VAX-31." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/d848914dex991.htm)) |
| mid-2026 | [Vaxcyte, Inc. topline data readout](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | scheduled | "We expect to announce topline data from the primary three-dose immunization series of the study in mid-2026, followed by topline data from the booster dose approximately nine months later." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000028/pcvx-20241231.htm)) |
| mid-2026 | [VAX-31 trial start](https://sec-api.dev/pdufa/vax-31) | PCVX |  | scheduled | "Company Expects to Initiate Phase 1 Adult Clinical Study for VAX-A1, a Vaccine Candidate to Prevent Disease Caused by Group A Strep, in Mid-2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/pcvx-20260506xexx991.htm)) |
| mid-2026 | [VAX-24 topline data readout](https://sec-api.dev/pdufa/vax-24) | PCVX |  | scheduled | "Todays results reinforce our commitment to advancing the broadest-spectrum PCVs to address the substantial invasive pneumococcal disease burden in the infant population, helping to reduce transmission and strengthen community immunity against the consequences of this devastating bacteria, said Jim Wassil, Executive Vice President and Chief Operating Officer of Vaxcyte. We continue to make significant progress across our PCVs, and for the infant indication, the complete VAX-24 data set is expected by the end of the year and the VAX-31 Phase 2 dose-finding study topline data is expected in mid-2026, with the balance of booster data up to 9 months later." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000119312525067901/d848914dex991.htm)) |
| May 6, 2026 | [Vaxcyte, Inc. earnings report](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | completed | "Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/pcvx-20260506xexx991.htm)) |
| August 5, 2026 | [Vaxcyte, Inc. earnings report](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | completed | "Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/pcvx-20260805xexx991.htm)) |
| September 17, 2026 | [PCV20 primary completion](https://sec-api.dev/pdufa/pcv20) | PCVX | Pneumococcal Disease | completed | "NCT07284654 (Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284654)) |
| Sep to Dec 2026 | [PCV20 topline data readout](https://sec-api.dev/pdufa/pcv20) | PCVX | Pneumococcal Disease | scheduled | "NCT07284654 (Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-17 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07284654)) |
| Q4 2026 | [VAX-31 topline data readout](https://sec-api.dev/pdufa/vax-31) | PCVX |  | scheduled | "Topline Safety, Tolerability and Immunogenicity Data from OPUS-1 Expected in Fourth Quarter of 2026; OPUS-2 and OPUS-3 Results Expected in First Half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/pcvx-20260506xexx991.htm)) |
| October 5, 2026 | [VAX-31 topline data readout](https://sec-api.dev/pdufa/vax-31) | PCVX |  | completed, positive | "SAN CARLOS, Calif., October 5, 2026 - Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced positive topline results from the OPUS-1 pivotal adult Phase 3 trial evaluating the safety, tolerability and immunogenicity of VAX-31, the Company's next-generation 31-valent pneumococcal conjugate vaccine (PCV) candidate, for the prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm)) |
| October 21, 2026 | [31-valent pneumococcal conjugate vaccine primary completion](https://sec-api.dev/pdufa/31-valent-pneumococcal-conjugate-vaccine) | PCVX | Pneumococcal Disease | completed | "NCT07365826 (A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-21 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365826)) |
| Oct 2026 to Jan 2027 | [31-valent pneumococcal conjugate vaccine topline data readout](https://sec-api.dev/pdufa/31-valent-pneumococcal-conjugate-vaccine) | PCVX | Pneumococcal Disease | scheduled | "NCT07365826 (A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-21 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07365826)) |
| October 25, 2026 | [PCV20 primary completion](https://sec-api.dev/pdufa/pcv20) | PCVX | Pneumococcal Disease | completed | "NCT07425392 (Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-25 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07425392)) |
| Oct 2026 to Jan 2027 | [PCV20 topline data readout](https://sec-api.dev/pdufa/pcv20) | PCVX | Pneumococcal Disease | scheduled | "NCT07425392 (Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-10-25 (ACTUAL); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07425392)) |
| November 4, 2026 | [Vaxcyte, Inc. earnings report](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | completed | "Vaxcyte Reports Third Quarter 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000051/pcvx-20261104xexx991.htm)) |
| 1H 2027 | [VAX-31 topline data readout](https://sec-api.dev/pdufa/vax-31) | PCVX |  | scheduled | "Enrollment in the modified study is expected to proceed by the end of the third quarter of this year with topline data from both the primary immunization series and the booster dose by the end of the first half of 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909425000096/pcvx20250806-exx991.htm)) |
| 1H 2027 | [Vaxcyte, Inc. topline data readout](https://sec-api.dev/companies/pcvx/catalysts) | PCVX |  | scheduled | "We expect to announce topline safety, tolerability and immunogenicity data for the Phase 2 randomized, dose-finding study from the primary three-dose immunization series and booster dose either sequentially or together by the end of the first half of 2027." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000007/pcvx-20251231.htm)) |
| 2H 2027 | [VAX-31 topline data readout](https://sec-api.dev/pdufa/vax-31) | PCVX | Disease Caused | scheduled | "Company Initiated Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults; Topline Data Expected in Second Half of 2027" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000041/pcvx-20260805xexx991.htm)) |
| December 2027 | [Vaxcyte, Inc. primary completion](https://sec-api.dev/companies/pcvx/catalysts) | PCVX | Pneumococcal Vaccines | scheduled | "NCT06720038 (A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06720038)) |
| Dec 2027 to Mar 2028 | [Vaxcyte, Inc. topline data readout](https://sec-api.dev/companies/pcvx/catalysts) | PCVX | Pneumococcal Vaccines | scheduled | "NCT06720038 (A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-12 (ESTIMATED); Lead Sponsor Vaxcyte, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06720038)) |
| 1H 2028 | [VAX-31 NDA/BLA submission](https://sec-api.dev/pdufa/vax-31) | PCVX |  | scheduled | "With OPUS-1 serving as the foundation of our planned Biologics License Application (BLA), we remain on track to announce results from the OPUS-2 and OPUS-3 Phase 3 trials in the first half of next year and, together with a manufacturing consistency study, we expect to submit a BLA in the first half of 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1649094/000164909426000051/pcvx-20261104xexx991.htm)) |

## Drugs

- [31-valent pneumococcal conjugate vaccine](https://sec-api.dev/pdufa/31-valent-pneumococcal-conjugate-vaccine): Pneumococcal Disease
- [PCV20](https://sec-api.dev/pdufa/pcv20): Pneumococcal Disease
- [VAX-24](https://sec-api.dev/pdufa/vax-24): 
- [VAX-31](https://sec-api.dev/pdufa/vax-31): invasive pneumococcal disease, disease caused, ipd in infants

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/pcvx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PCVX catalysts: Vaxcyte, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/pcvx/catalysts

```bibtex
@misc{secapidev_companies_pcvx_catalysts_20261116,
  title        = {PCVX catalysts: Vaxcyte, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/pcvx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_pcvx_catalysts_20261116","title":"PCVX catalysts: Vaxcyte, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/pcvx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
